CASES

Insights Into Acute Myeloid Leukemia (AML)
Monday, August 17, 2020

Speaker: Elias Jabbour, MD
Moderator: Naval Daver, MD

AGENDA

Time (EST)	Topic
6.00 PM – 6.15 PM (15 min)	**Introduction** • Program overview • Baseline ARS questions

6.15 PM – 7.45 PM (90 min)	**Treatment of AML**
	• Overview of current data
	  – Factors guiding first-line therapy
	    ▪ Impact of age, cytogenetics, molecular markers, comorbidities, PS, and etiology (primary, therapy-related, myelodysplasia-related changes) on induction therapy selection
	    ▪ Standard 7+3 vs liposomal daunorubicin/cytarabine vs other intensive regimens (FLAG-IDA) vs hypomethylating agents and/or low-dose cytarabine vs gemtuzumab
	    ▪ Postinduction consolidation therapy (HiDAC, allo-SCT)
	  – Integration of novel agents approved and under investigation (FLT3 inhibitors, BCL2 inhibitors, Hedgehog pathway inhibitors, IDH1 inhibitors)
	  – Maintenance therapy?
	  – Role of MRD
	  – Factors guiding second-line and subsequent therapy
	    ▪ Biomarkers at relapse
	    ▪ Patient age, timing of relapse (<12 months vs >12 months), and role of reinduction or HCT
	    ▪ Targeted therapy for *FLT3*-positive, *CD33*-positive, and *IDH1*- or *IDH2*-positive patients
	• Reaction and discussion

7.45 PM – 8.00 PM (15 min)	**Break**

8.00 PM – 8.45 PM (45 min)	**Promising Strategies in AML**
	• ARS questions
	• Overview of current data
	  – Anti-CD47 antibody
	  – APR-246 for *p53* mutant AML
	  – Anti-CD70 antibody
	• Reaction and discussion

8.45 PM – 9.00 PM (15 min)	**Key Takeaways and Meeting Evaluation**